263 related articles for article (PubMed ID: 17855727)
41. Pulmonary aspergillosis: recent advances.
Thompson GR; Patterson TF
Semin Respir Crit Care Med; 2011 Dec; 32(6):673-81. PubMed ID: 22167395
[TBL] [Abstract][Full Text] [Related]
42. Does pre-exposure of Aspergillus fumigatus to voriconazole or posaconazole in vitro affect its virulence and the in vivo activity of subsequent posaconazole or voriconazole, respectively? A study in a fly model of aspergillosis.
Lamaris GA; Ben-Ami R; Lewis RE; Kontoyiannis DP
J Antimicrob Chemother; 2008 Sep; 62(3):539-42. PubMed ID: 18544603
[TBL] [Abstract][Full Text] [Related]
43. In Vivo Synergy of Amphotericin B plus Posaconazole in Murine Aspergillosis.
Martin-Vicente A; Capilla J; Guarro J
Antimicrob Agents Chemother; 2016 Jan; 60(1):296-300. PubMed ID: 26503653
[TBL] [Abstract][Full Text] [Related]
44. In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility.
Spreghini E; Orlando F; Giannini D; Barchiesi F
J Antimicrob Chemother; 2010 Oct; 65(10):2158-63. PubMed ID: 20667887
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of the efficacy of a posaconazole and anidulafungin combination in a murine model of pulmonary aspergillosis due to infection with Aspergillus fumigatus.
Bedin Denardi L; Pantella Kunz de Jesus F; Keller JT; Weiblen C; de Azevedo MI; Oliveira V; Morais Santurio J; Hartz Alves S
Diagn Microbiol Infect Dis; 2018 Jan; 90(1):40-43. PubMed ID: 29126660
[TBL] [Abstract][Full Text] [Related]
46. Posaconazole prophylaxis in experimental azole-resistant invasive pulmonary aspergillosis.
Seyedmousavi S; Mouton JW; Melchers WJ; Verweij PE
Antimicrob Agents Chemother; 2015 Mar; 59(3):1487-94. PubMed ID: 25534731
[TBL] [Abstract][Full Text] [Related]
47. Resistance to amphotericin B does not emerge during treatment for invasive aspergillosis.
Moosa MY; Alangaden GJ; Manavathu E; Chandrasekar PH
J Antimicrob Chemother; 2002 Jan; 49(1):209-13. PubMed ID: 11751792
[TBL] [Abstract][Full Text] [Related]
48. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis.
Murphy M; Bernard EM; Ishimaru T; Armstrong D
Antimicrob Agents Chemother; 1997 Mar; 41(3):696-8. PubMed ID: 9056016
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis.
Denning DW; Hall L; Jackson M; Hollis S
Antimicrob Agents Chemother; 1995 Aug; 39(8):1809-14. PubMed ID: 7486923
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis.
Allendoerfer R; Loebenberg D; Rinaldi MG; Graybill JR
Antimicrob Agents Chemother; 1995 Jun; 39(6):1345-8. PubMed ID: 7574528
[TBL] [Abstract][Full Text] [Related]
51. Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy.
Walsh TJ; Garrett K; Feurerstein E; Girton M; Allende M; Bacher J; Francesconi A; Schaufele R; Pizzo PA
Antimicrob Agents Chemother; 1995 May; 39(5):1065-9. PubMed ID: 7625790
[TBL] [Abstract][Full Text] [Related]
52. In vitro and in vivo activities of posaconazole and amphotericin B in a murine invasive infection by Mucor circinelloides: poor efficacy of posaconazole.
Salas V; Pastor FJ; Calvo E; Alvarez E; Sutton DA; Mayayo E; Fothergill AW; Rinaldi MG; Guarro J
Antimicrob Agents Chemother; 2012 May; 56(5):2246-50. PubMed ID: 22290952
[TBL] [Abstract][Full Text] [Related]
53. Vitamin D and experimental invasive aspergillosis.
Sirivoranankul C; Martinez M; Chen V; Clemons KV; Stevens DA
Med Mycol; 2014 Nov; 52(8):847-52. PubMed ID: 25231772
[TBL] [Abstract][Full Text] [Related]
54. [Progress in combination therapy for invasive aspergillosis].
Luo L; Tong Z
Zhonghua Jie He He Hu Xi Za Zhi; 2014 Jan; 37(1):41-4. PubMed ID: 24694973
[No Abstract] [Full Text] [Related]
55. Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice.
Connolly P; Wheat LJ; Schnizlein-Bick C; Durkin M; Kohler S; Smedema M; Goldberg J; Brizendine E; Loebenberg D
Antimicrob Agents Chemother; 2000 Oct; 44(10):2604-8. PubMed ID: 10991831
[TBL] [Abstract][Full Text] [Related]
56. In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatus.
Otsubo T; Maesaki S; Hossain MA; Yamamoto Y; Tomono K; Tashiro T; Seki J; Tomii Y; Sonoke S; Kohno S
Antimicrob Agents Chemother; 1999 Mar; 43(3):471-5. PubMed ID: 10049253
[TBL] [Abstract][Full Text] [Related]
57. Role of nebulized amphotericin B in the management of allergic bronchopulmonary aspergillosis in cystic fibrosis: Case report and review of literature.
Casciaro R; Naselli A; Cresta F; Ros M; Castagnola E; Minicucci L
J Chemother; 2015 Oct; 27(5):307-11. PubMed ID: 24824366
[TBL] [Abstract][Full Text] [Related]
58. Combination therapy in a model of pulmonary aspergillosis.
Schmitt HJ; Bernard EM; Edwards FF; Armstrong D
Mycoses; 1991; 34(7-8):281-5. PubMed ID: 1803227
[TBL] [Abstract][Full Text] [Related]
59. Antifungal Liposomes Directed by Dectin-2 Offer a Promising Therapeutic Option for Pulmonary Aspergillosis.
Ambati S; Ellis EC; Pham T; Lewis ZA; Lin X; Meagher RB
mBio; 2021 Feb; 12(1):. PubMed ID: 33622715
[TBL] [Abstract][Full Text] [Related]
60. Nebulised liposomal amphotericin B for Aspergillus lung diseases: case series and literature review.
Godet C; Goudet V; Laurent F; Le Moal G; Gounant V; Frat JP; Cateau E; Roblot F; Cadranel J
Mycoses; 2015 Mar; 58(3):173-80. PubMed ID: 25690951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
